Floatz logo

FES F-18

Metastatic Hormone Receptor-Positive Breast Carcinoma

University of WashingtonSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Metastatic Hormone Receptor-Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Everolimus
Ellipses Pharma
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB
Ribociclib
BeOne Medicines
Phase 4BBB

View all 50 →

Same molecule, other indications

FES F-18 is also rated in:

breast cancerDormant
BB
Indicative ·
64 / 100
View asset →
breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
invasive lobular breast carcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →